Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro announces a new research collaboration
2025-01-17
New Year, New Collaboration!
We’re excited to kick off the new year with a new research collaboration! With the Salipro® platform, these projects focus on the stabilization of the most challenging drug targets in the field, aiming to transform difficult membrane proteins into opportunities for therapeutic advancements.
We look forward to the advancements that these projects will bring in this year committed to our mission to make the undruggable druggable!
Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore
2024-12-05
Salipro Biotech strengthens its global intellectual property portfolio with granted patents in Singapore and Australia, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets.
Stockholm, Sweden, December 5, 2024 – Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro® platform technology, a novel and proprietary method for directly isolating and purifying native membrane proteins, which are important targets for many therapeutic drugs. The Salipro® platform enables entirely novel drug discovery programs, including antibody discovery, small molecule drug screening and structure-based drug design.
The patents, entitled “Production of Salipro® Particles” (Australian Patent No. 2020257991; Singaporean Patent No. 11202111111U), cover processes implemented in the Salipro® platform and represent an important milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.
Access the full press release.
Salipro to join the upcoming PEGS Europe conference
2024-10-29
Salipro Biotech is heading to PEGS Europe 2024, taking place in Barcelona (Spain), November 5-7!
Our Business Development Director, Peter Jahnmatz, will be there to present new exciting data from our latest collaborations on GPCR-targeted drug discovery.
If you are also attending, take the chance to meet Peter by his poster (B93) to exchange ideas on how the Salipro® platform can advance your drug discovery programs against complex membrane protein targets.
Let’s meet at PEGS and discuss exciting collaborations!